La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
76 hedge funds and large institutions have $86M invested in La Jolla Pharmaceutical Company in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 17 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
8% more capital invested
Capital invested by funds: $79.4M → $86M (+$6.62M)
4% more funds holding
Funds holding: 73 → 76 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less call options, than puts
Call options by funds: $378K | Put options by funds: $444K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.75M |
| 2 |
Two Sigma Advisers
New York
|
+$2.28M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.14M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.52M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.03M |
| 2 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$614K |
| 3 |
PP
PDT Partners
New York
|
-$463K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$358K |
| 5 |
BlackRock
New York
|
-$353K |
LJPC Hedge Fund Activity: Q2 2020 in Review
76 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q2 2020, worth a combined $86M — up 8.3% from $79.4M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new LJPC positions and 17 closed out — a net gain of 3 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $3.75M. The largest seller was Fidelity Investments, cutting an estimated $7.03M.
- 76 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q2 2020, up from 73 in Q1 2020.
- Funds reported $86M of La Jolla Pharmaceutical Company stock for Q2 2020, up 8.3% quarter-over-quarter.
- 20 funds opened new La Jolla Pharmaceutical Company positions in Q2 2020 and 17 closed out, a net change of +3 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q2 2020 was Tang Capital Management, an estimated $3.75M added.
- The largest La Jolla Pharmaceutical Company seller in Q2 2020 was Fidelity Investments, an estimated $7.03M sold.
Based on aggregated 13F filings for Q2 2020.